Welcome to our dedicated page for Innospec SEC filings (Ticker: IOSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innospec Inc. filings document the financial reporting, governance and capital-return disclosures of a specialty chemicals operating company. Form 8-K reports record quarterly and annual results, segment commentary for Performance Chemicals, Fuel Specialties and Oilfield Services, Regulation FD disclosures, semi-annual dividends and board-authorized common stock repurchase programs.
The company’s proxy materials describe annual meeting matters, director elections, executive compensation votes, auditor ratification and related governance procedures. Its filings also identify IOSP common stock as a NASDAQ-listed security and provide formal disclosure around results of operations, financial condition, risk-related business context and shareholder voting matters.
Innospec Inc. reported a change in its Board of Directors. Effective June 2, 2026, the Board increased its size from seven to eight members and appointed Shelley Bausch as a Class II director, starting July 1, 2026 and serving until the 2027 annual stockholder meeting or until a successor is elected and qualified.
She will also join the Audit Committee on July 1, 2026. As a non-employee director, Ms. Bausch will receive a standard annual cash retainer of $100,000, plus an additional annual $5,000 for Audit Committee service, both paid quarterly. She will be eligible for an annual equity grant with an expected value of $125,000 under the company’s Long-Term Incentive Omnibus Plan, similar to awards granted in February 2025, which vest after three years. She may also earn $2,000 per additional day for extra services at the CEO’s request, and the company states there are no related-party transactions requiring disclosure.
Innospec Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 8, 2026. As of the March 13, 2026 record date, 24,890,467 shares of common stock were outstanding and entitled to vote, and 22,661,185 shares were present or represented by proxy, about 91% of eligible shares.
Stockholders re-elected Class I directors Elizabeth K. Arnold and Claudia P. Poccia. They also approved the advisory vote on executive compensation and ratified the appointment of the company’s independent registered public accounting firm for 2026, based on the final certified vote results.
Innospec Inc. reported first-quarter 2026 revenue of $453.2 million, up 3% from $440.8 million a year earlier, while GAAP diluted EPS declined to $1.22 from $1.31. Adjusted non-GAAP EPS fell to $1.05 from $1.42 as margins weakened in certain segments.
Performance Chemicals revenue rose slightly to $169.4 million, but operating income dropped 46% to $10.7 million, reflecting impacts from a U.S. winter storm. Fuel Specialties delivered another solid quarter with revenue of $181.6 million, up 7%, and operating income of $37.8 million, up 2%. Oilfield Services revenue was stable at $102.2 million, with operating income improving 37% to $5.6 million.
The company ended the quarter with $289.1 million in cash and no debt. The board increased the semi-annual dividend by 10% to $0.92 per share, payable May 29, 2026, and authorized a new $75 million share repurchase program over three years, replacing a prior $50 million authorization.
Innospec Inc reported that Vanguard Capital Management beneficially owned 1,300,194 shares of Common Stock, representing 5.22% of the class as of 03/31/2026. The filing shows Vanguard has sole dispositive power over 1,300,194 shares and sole voting power for 185,596 shares. The Schedule 13G was signed on 04/30/2026.
Vanguard Portfolio Management reported beneficial ownership of 1,870,254 shares of Innospec Inc common stock, equal to 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 1,870,254 shares and sole voting power for 10,163 shares. The filing notes holdings include securities held for Vanguard funds and client accounts managed by affiliates.
Innospec Inc Schedule 13G/A amendment: The Vanguard Group reports beneficial ownership of 0 shares (0%) of Common Stock in Amendment No. 12. The filing notes an internal realignment of Vanguard and that certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
Innospec Inc. has called its 2026 annual meeting of stockholders for May 8, 2026, at The St. Regis New York. Stockholders of record on March 13, 2026, when 24,890,467 common shares were outstanding, may vote.
They will elect two Class I directors to terms ending in 2029, cast an advisory vote on executive compensation, and ratify the independent auditor. The proxy describes a strongly independent board with a separate non-executive chair, anti-hedging and anti-pledging policies, majority-vote resignation guidelines, and director stock ownership requirements.
Innospec also highlights sustainability and human-capital initiatives, including reduced scope 1 and 2 emissions versus 2014, global safety programs, extensive compliance training, and community and employee engagement, while detailing non‑employee director fees and equity-based compensation.
INNOSPEC INC. director Milton C. Blackmore reported amended details of recent stock sales. On February 27, 2026, he completed two open-market sales of the company’s common stock totaling 594 shares. One block of 287 shares was sold at a weighted average price of $76.30 per share, and another 307 shares at a weighted average price of $76.79 per share. After these transactions, his directly held stake changed in two steps to 10,837 shares and then 10,530 shares of common stock. This amended Form 4 corrects previously reported transaction prices and notes that the sale prices reflect weighted averages across multiple trades within stated ranges.